|
Article Cited by others ORIGINAL ARTICLE
Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study
Gupta Sunil, Shaikh Shehla, Joshi Pooja, Bhure Shraddha, Suvarna Viraj
Year : 2017| Volume: 21| Issue : 2 | Page no: 286-292 | This article has been cited by | | 1 |
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020 |
|
| | Rajeev Chawla,S. V. Madhu,B. M. Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra | | | International Journal of Diabetes in Developing Countries. 2020; 40(S1): 1 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study |
|
| | Manash P Baruah,Sanjay Kalra | | | European Endocrinology. 2019; 15(2): 113 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis |
|
| | Jennifer R Donnan,Catherine A Grandy,Eugene Chibrikov,Carlo A Marra,Kris Aubrey-Bassler,Karissa Johnston,Michelle Swab,Jenna Hache,Daniel Curnew,Hai Nguyen,John-Michael Gamble | | | BMJ Open. 2019; 9(1): e022577 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians |
|
| | Awadhesh Kumar Singh,Ambika G. Unnikrishnan,Abdul H. Zargar,Ajay Kumar,Ashok K. Das,Banshi Saboo,Binayak Sinha,Kalyan Kumar Gangopadhyay,Pradeep G. Talwalkar,Samit Ghosal,Sanjay Kalra,Shashank Joshi,Surendra Kumar Sharma,Usha Sriram,Viswanathan Mohan | | | Diabetes Therapy. 2019; | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis |
|
| | Hongmei Wang,Jiadan Yang,Xi Chen,Feng Qiu,Juan Li | | | Clinical Therapeutics. 2019; | | | [Pubmed] [Google Scholar] [DOI] | | | 6 |
Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes |
|
| | Habib Yaribeygi,Stephen L. Atkin,Amirhossein Sahebkar | | | Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(2): 1679 | | | [Pubmed] [Google Scholar] [DOI] | | | 7 |
Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
|
| | Xia Dai,Zu-chun Luo,Lu Zhai,Wen-piao Zhao,Feng Huang | | | Diabetes Therapy. 2018; | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
|
|
